RLAY Relay Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1812364 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.9%
TTM net income YoY1.3%
TTM EPS YoY12.8%
Revenue 3-yr CAGR-26.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,094.6%
Net margin-2,837.0%
FCF margin—
EBITDA margin-3,077.7%
Returns
ROE-41.2%
ROA-37.4%
ROIC (approx.)-41.8%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets9.2%
Debt / equity0.00x
Current ratio14.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $15.36M | $10.01M | $25.55M | $1.38M | $3.03M |
| R&D expense | $261.38M | $319.09M | $330.02M | $246.35M | $172.65M |
| SG&A expense | $56.71M | $76.59M | $74.95M | $65.98M | $57.39M |
| Operating income | -$302.74M | -$372.47M | -$373.00M | -$299.27M | -$364.70M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$276.48M | -$337.71M | -$341.97M | -$290.51M | -$363.87M |
| EBITDA | -$299.18M | -$367.00M | -$367.73M | -$295.14M | -$360.77M |
| EPS (basic) | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 |
| EPS (diluted) | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 |
| Weighted avg. shares (diluted) | — | — | — | 112.23M | 95.14M |
| Balance sheet | |||||
| Cash & equivalents | $84.02M | $126.41M | $146.44M | $154.37M | $282.70M |
| Receivables | — | — | — | $306,000 | $403,000 |
| Current assets | $578.28M | $809.20M | $770.10M | $1.02B | $976.24M |
| PP&E, net | $1.73M | $5.91M | $10.90M | $11.63M | $6.54M |
| Intangibles | — | — | $2.30M | $2.30M | $2.30M |
| Total assets | $621.33M | $871.30M | $843.98M | $1.10B | $1.01B |
| Current liabilities | $25.58M | $50.73M | $30.27M | $63.71M | $24.32M |
| Total liabilities | $54.27M | $93.50M | $91.98M | $149.55M | $110.64M |
| Shareholders' equity | $567.06M | $777.79M | $752.00M | $950.22M | $897.81M |
| Shares outstanding | 173.87M | 167.76M | 127.46M | 121.11M | 108.21M |
| Cash flow statement | |||||
| Operating cash flow | -$235.46M | -$249.11M | -$300.32M | -$229.49M | -$74.41M |
| Capital expenditure | $410,000 | $2.02M | $4.13M | $9.06M | $3.47M |
| Free cash flow | -$235.87M | -$251.12M | -$304.44M | -$238.55M | -$77.88M |
| Investing cash flow | $192.80M | -$41.08M | $257.63M | -$188.75M | -$479.51M |
| Financing cash flow | $1.60M | $270.15M | $34.75M | $289.91M | $388.09M |
| Depreciation & amortization | $3.56M | $5.46M | $5.27M | $4.13M | $3.92M |
| Stock-based compensation | $62.42M | $94.14M | $86.03M | $56.14M | $48.45M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.